Neuropeptide S: Complete Research Profile — Arousal, Anxiolysis, Fear Extinction, and the NPSR1 Panic Disorder Genetics (2026)

# Neuropeptide S: Complete Research Profile — Arousal, Anxiolysis, Fear Extinction, and the NPSR1 Panic Disorder Genetics (2026)

Most compounds that promote wakefulness also amplify anxiety — caffeine, amphetamine, modafinil, and corticotropin-releasing factor all promote arousal at the cost of increased stress or anxiety responses. The reverse is equally true: most anxiolytics sedate. This apparent pharmacological trade-off was shattered in 2004 when a new neuropeptide was characterized: Neuropeptide S (NPS). ICV administration of NPS in rodents simultaneously increased wakefulness and reduced anxiety — a behavioral profile with no classical pharmacological analog. This paradox drove intense research into NPS and its receptor (NPSR1), revealing a multifunctional peptide system involved in arousal, memory, fear extinction, asthma, and human psychiatric genetics.

Discovery: Reverse Pharmacology and Orphan Receptor Deorphanization

NPS was identified in 2004 by Xu and colleagues through orphan receptor reverse pharmacology — a strategy that begins with an uncharacterized receptor and screens peptide libraries for agonist activity. The target receptor, then known as GPR154 (also called GPRA, G protein-coupled receptor for asthma susceptibility, based on its earlier identification as an asthma GWAS hit), was expressed in HEK293 cells and tested against a library of synthetic peptides derived from predicted prepropeptide sequences.

The activating peptide was a 20-amino acid sequence beginning with serine at its N-terminus — a structural feature that became the basis for the peptide's name: Neuropeptide S (the S referring to the initial serine residue). Publication in Cell (Xu et al., 2004;) simultaneously identified the peptide and demonstrated its behavioral paradox: ICV injection in mice promoted wakefulness while reducing anxiety-like behavior in the elevated plus maze.

The receptor was renamed NPSR1 (neuropeptide S receptor 1) upon deorphanization. No second NPS receptor has been identified, though splice variants of NPSR1 with different signal transduction properties have been characterized.

Molecular Biology: Structure, Processing, and the NPS Gene

Peptide Structure

The NPS precursor (prepro-NPS) is a 90-amino acid protein encoded by the NPS gene. Proteolytic processing releases the mature 20-residue peptide:

NPS (1-20): SFRNGVGTGMKKTSFQRAKS

Structure-activity relationship studies reveal:

• •The N-terminal Ser¹ is critical: substitution of Ser¹ with Ala abolishes agonist activity, converting NPS into a partial antagonist (reflecting the importance of this residue in NPSR1 engagement)
• •Residues 2-10 contain the core pharmacophore required for receptor activation
• •Truncated fragments as short as NPS(1-10) retain significant NPSR1 activity
• •C-terminal residues contribute to binding affinity but not intrinsic efficacy

This N-terminal Ser dependence distinguishes NPS from most classical neuropeptides, where C-terminal modifications are typically critical.

NPS Gene and Conservation

The NPS gene is located on chromosome 10q26 in humans. NPS is highly conserved across vertebrates — the human sequence is identical to rat NPS in 18 of 20 residues, and orthologs have been identified in fish, amphibians, and birds. This evolutionary conservation suggests fundamental physiological roles maintained across vertebrate lineages.

Expression Pattern

NPS-expressing neurons are concentrated in a limited number of brainstem nuclei, creating a focused source of a widely projecting signaling molecule:

Primary NPS neuron populations:

• •Locus coeruleus (LC) / peri-LC region: The major NPS nucleus; noradrenergic LC neurons project broadly to the forebrain and are the principal arousal/noradrenaline center
• •Lateral dorsal tegmentum (LDTg): Cholinergic arousal center
• •Barrington's nucleus: Important for autonomic and micturition control
• •Principal sensory trigeminal nucleus: Sensory processing

NPSR1 (receptor) expression (in contrast, is broadly distributed):

• •Cortex (multiple layers)
• •Hippocampus (CA1-CA3, dentate gyrus)
• •Amygdala (basolateral and central nuclei)
• •Hypothalamus (paraventricular nucleus, lateral hypothalamus)
• •Thalamus
• •Olfactory bulb
• •Brainstem

The anatomical arrangement — brainstem NPS source neurons projecting to limbic and cortical NPSR1-expressing targets — is consistent with a system designed to broadly modulate arousal, emotion, and cognitive state from a central brainstem "hub."

NPSR1 Signal Transduction

NPSR1 couples to multiple G protein pathways depending on cellular context:

Primary signaling:

• •Gαs: Increases intracellular cAMP via adenylyl cyclase stimulation
• •Gαq/11: Activates PLCβ → IP3/DAG → intracellular Ca²⁺ mobilization

NPSR1 is thus an excitatory GPCR — in contrast to the inhibitory Gαi-coupled opioid and somatostatin receptors. This excitatory character is consistent with NPS's arousal-promoting and memory-enhancing pharmacology.

Downstream cascades:

• •ERK1/2 phosphorylation (both cAMP-dependent and Ca²⁺-dependent routes)
• •PKA activation (from Gαs/cAMP)
• •PKC activation (from Gαq/DAG)
• •β-arrestin recruitment → receptor internalization and biased signaling

The Gαs/cAMP pathway is thought to predominate in cortical and limbic neurons relevant to NPS's cognitive and anxiolytic effects, while Gαq activation in hypothalamic contexts may mediate food intake and stress axis effects.

NPSR1 Splice Variants

Two main NPSR1 splice variants exist:

• •NPSR1-A: A shorter isoform (7 transmembrane helices, full receptor)
• •NPSR1-B: A longer isoform with an extended C-terminal tail that alters intracellular trafficking and β-arrestin recruitment

The relative expression of splice variants varies across brain regions and may contribute to tissue-specific NPS pharmacology.

The Arousal-Anxiolysis Paradox

Arousal and Wakefulness

ICV NPS in rodents produces:

• •Increased locomotor activity
• •Reduced time in NREM and REM sleep (decreased total sleep time)
• •Enhanced wakefulness duration
• •EEG desynchronization (high-frequency, low-amplitude waveforms characteristic of wakefulness)

The arousal-promoting effects are consistent with NPS's origin from LC-proximal neurons. The LC-norepinephrine system is the canonical arousal system, and LC activation mirrors NPS's wakefulness effects. NPS likely activates LC neurons and promotes norepinephrine release in forebrain targets, contributing to cortical arousal.

Compared to other arousal peptides (orexin/hypocretin, histamine), NPS produces robust but shorter-lasting arousal with different EEG spectral characteristics — suggesting partially overlapping but non-identical arousal mechanisms.

Anxiolysis: The Paradox Resolved

Simultaneously with arousal promotion, NPS reduces anxiety-like behavior:

• •Elevated plus maze: increased open-arm time and entries
• •Light-dark box: increased time in the light compartment
• •Open field: reduced anxiety-related behaviors without reducing total locomotion
• •Social interaction test: increased social interaction

This anxiolytic profile resembles diazepam/benzodiazepines in behavioral readouts, yet NPS promotes wakefulness while benzodiazepines are sedating. The mechanistic basis of NPS anxiolysis is still being elucidated, but key candidates include:

1. Amygdala NPSR1: NPS suppresses amygdala anxiety circuit output through NPSR1-expressing basolateral amygdala neurons

2. GABA modulation: NPS may indirectly enhance GABAergic inhibition in limbic circuits

3. CRF attenuation: NPS can suppress CRF-mediated anxiety responses, dissociating arousal (maintained by NE) from anxiety (reduced by CRF suppression)

4. Locus coeruleus modulation: High NPS at LC may paradoxically reduce tonic anxiety-driving NE fluctuations by stabilizing LC firing

This pharmacological profile — simultaneous arousal promotion and anxiolysis — has made NPS a subject of intense interest as a potential template for novel psychopharmacological agents.

Fear Memory, Extinction, and PTSD Research

Fear Extinction Facilitation

One of the most pharmacologically important properties of NPS is its ability to facilitate fear extinction — the process by which conditioned fear responses are suppressed through new inhibitory learning.

In rodent Pavlovian fear conditioning paradigms:

• •Post-training ICV NPS does not impair initial fear memory consolidation
• •NPS administered before extinction training dramatically accelerates fear extinction
• •NPS reduces spontaneous recovery of extinguished fear
• •NPS reduces renewal of fear following context change

Fear extinction is mediated by the infralimbic prefrontal cortex (IL-PFC) projecting to the amygdala, and NPSR1 is expressed in both structures. NPS is proposed to facilitate extinction by:

• •Enhancing IL-PFC activity and output to amygdala extinction neurons
• •Reducing amygdala basolateral nucleus (BLA) excitability to conditioned stimuli
• •Promoting consolidation of the extinction memory trace

PTSD Relevance

Impaired fear extinction is a core feature of post-traumatic stress disorder (PTSD). The ability of NPS to facilitate extinction even in animals with extinction-resistant fear memories (produced by severe stressors) has generated research interest in NPS-based pharmacological enhancement of extinction-based therapies.

This parallels clinical interest in other extinction-facilitating agents (MDMA, D-cycloserine, yohimbine) as adjuncts to exposure therapy for PTSD. NPS's combined arousal/anxiolytic profile may be particularly suited to the exposure therapy context, where reduced avoidance behavior and maintained engagement with the therapeutic environment are desirable.

Human Genetics: NPSR1 Polymorphisms in Panic Disorder and Asthma

The Asthma Connection

NPSR1 was independently identified as an asthma susceptibility gene before NPS was discovered. Laitinen et al. (2004) identified GPRA (NPSR1) through positional cloning in Finnish asthma families, reporting that specific NPSR1 haplotypes were associated with asthma and bronchial hyperresponsiveness. NPSR1 expression is elevated in bronchial epithelium and smooth muscle of asthma patients.

The NPS-NPSR1 system likely contributes to airway inflammation through immune cell modulation (NPSR1 is expressed on lymphocytes and mast cells) and potentially through neurogenic airway inflammation via NPSR1-expressing airway sensory neurons.

The Asn107Ile Variant: Higher-Activity NPSR1

The most-studied NPSR1 variant is the Asn107Ile nonsynonymous single-nucleotide polymorphism (rs324981). The Ile107 variant:

• •Has approximately 10-fold higher constitutive and agonist-stimulated Gαs signaling compared to Asn107
• •Is more abundant in psychiatric populations in some studies
• •Is associated with altered anxiety measures in healthy volunteers

Panic Disorder Association

Multiple research groups have reported associations between NPSR1 variants (including Asn107Ile) and panic disorder:

• •Okamura et al. (2007) reported NPSR1 association with panic disorder in Japanese cohorts
• •Domschke et al. (2011) replicated the association and demonstrated that the Ile107 variant moderates response to cognitive-behavioral therapy in panic disorder — a gene-by-treatment interaction
• •The paradox: a higher-activity NPSR1 variant (Ile107) — which should produce more NPS-like effects including anxiolysis — is associated with greater panic vulnerability. This suggests complex circuit-level effects where NPSR1 hyperactivity in certain contexts may sensitize threat-detection circuits rather than uniformly reducing anxiety

The NPSR1 human genetics data represent one of the strongest neuropeptide-psychiatric disorder genetics associations in the anxiety disorder field, positioning NPS research at the translational frontier between rodent pharmacology and human psychiatric genetics.

Sleep Architecture and Circadian Modulation

NPS opposes cortistatin's sleep-promoting effects: while cortistatin increases slow-wave sleep, NPS reduces it. NPS's arousal-promoting properties extend to:

• •Delaying sleep onset
• •Reducing total sleep time at low-moderate ICV doses
• •Increasing wakefulness and locomotor activity particularly during the inactive (light) phase in nocturnal rodents

NPSR1 knockout (NPSR1−/−) mice show:

• •Slightly increased NREM sleep
• •Altered sleep microarchitecture
• •Modified responses to sleep deprivation
• •Blunted response to NPS (confirming NPSR1 as the primary mediator of sleep effects)

Sleep deprivation increases NPS expression in LC-proximal brainstem neurons, suggesting that endogenous NPS participates in homeostatic sleep pressure modulation — potentially as a wake-promoting signal that increases under sleep debt.

NPS in Feeding and Metabolic Research

Central NPS reduces food intake in rodents at doses that increase locomotor activity — an effect that may be secondary to arousal-driven suppression of feeding rather than a primary satiety mechanism. Specifically:

• •ICV NPS reduces short-term food intake in food-deprived rodents
• •The anorexigenic effect is attenuated by the NPSR1 antagonist SHA 68
• •NPS does not appear to activate arcuate POMC neurons directly (unlike GLP-1 or leptin)
• •The feeding suppression may be mediated through CRF pathway activation (as NPS activates PVN CRF neurons)

NPS food intake effects are not as potent as dedicated anorexigenic peptides (e.g., NMU, GLP-1, CCK) and are likely secondary to the peptide's primary arousal/stress functions rather than representing a primary metabolic regulatory role.

Drug Addiction and Reward Research

NPSR1 is expressed in the mesolimbic dopamine system (VTA, NAc), and NPS modulates addiction-relevant behaviors:

Opioid addiction:

• •ICV NPS reduces morphine-induced conditioned place preference
• •NPS attenuates stress-induced reinstatement of morphine seeking
• •NPS facilitates extinction of morphine CPP

Cocaine:

• •NPS reduces cocaine-induced reinstatement of drug seeking in some protocols
• •Effects may be mediated through NPSR1 in the amygdala modulating cue-induced craving

Alcohol:

• •Preclinical data suggest NPS reduces alcohol consumption in high-drinking rat strains
• •The SHA 68 antagonist potentiates alcohol consumption in some models

These findings position NPS within the growing literature on neuropeptide systems as potential targets for addiction medicine research, particularly given its favorable anxiolytic profile (anxiety being a major driver of substance use).

Research Tools

Current Research Frontiers (2024-2026)

Panic disorder pharmacology: Whether NPSR1 modulators can target the specific amygdala-LC circuit components dysregulated in panic disorder; investigation of allelic-specific drug responses for Asn107Ile carriers.

Exposure therapy augmentation: NPS as a pharmacological adjunct to extinction-based therapies for PTSD and phobias; parallels with active clinical investigation of other extinction-facilitating agents.

NPS in asthma neuroimmunology: NPSR1 on airway immune cells and sensory neurons; potential for NPSR1 antagonism in allergic airway disease.

Selective NPSR1 modulators: Development of blood-brain-barrier penetrant NPSR1 agonists and antagonists with improved pharmacokinetics for in vivo studies and potential clinical testing.

Sex differences: Female rodents show greater NPS-induced anxiolysis than males in some paradigms; mechanisms and translational relevance being characterized.

Conclusion

Neuropeptide S is defined pharmacologically by a single paradox: it wakes you up and calms you down simultaneously. This behavioral profile — impossible to achieve with classical sedating anxiolytics or stimulating arousal agents — reflects NPS's unique circuit-level action on a system evolved to modulate alertness without anxiety escalation. The brainstem-limbic architecture of the NPS system, the facilitation of fear extinction through amygdala NPSR1, and the human genetics of NPSR1 in panic disorder together make NPS one of the most translationally compelling unexplored neuropeptide systems.

For researchers studying anxiety, PTSD, sleep, addiction, or the neurobiology of the arousal-anxiety interface, NPS and NPSR1 represent a mechanistically differentiated target with a compelling mix of behavioral pharmacology, circuit-level biology, and human genetic validation.

---

References

2. Laitinen T et al. "Characterization of a common susceptibility locus for asthma-related traits." Science 2004;304(5668):300-304. PMID: 15073379

3. Reinscheid RK, Xu YL. "Neuropeptide S and its receptor: a newly deorphanized G protein-coupled receptor system." Neuroscientist 2005;11(6):532-538. PMID: 16282596

4. Jungling K et al. "Neuropeptide S-mediated control of fear expression and extinction: role of intercalated amygdala neurons." Neuron 2008;59(2):298-310. PMID: 18667158

8. Pape HC, Jüngling K. "The neuropeptide S system in sleep-related control." J Sleep Res 2014. PMID: 24716635

---

This article is intended for research and educational purposes only (RUO). Neuropeptide S, NPSR1 ligands, and related compounds discussed herein are investigational research tools. No compound described has been evaluated by regulatory authorities for safety or efficacy in humans for the applications described. This content does not constitute medical advice, clinical guidance, or encouragement of human use.